Edition:
United Kingdom

Genscript Biotech Corp (1548.HK)

1548.HK on Hong Kong Stock

11.18HKD
23 Jan 2019
Change (% chg)

-- (--)
Prev Close
HK$11.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,797,872
52-wk High
HK$34.00
52-wk Low
HK$8.60

Latest Key Developments (Source: Significant Developments)

Genscript Biotech Corp Says Unit Entered License And Development Agreement
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Genscript Biotech Corp <1548.HK>::UNIT ENTERED INTO A LICENSE AND DEVELOPMENT AGREEMENT RELATING TO A BISPECIFIC ANTIBODY PRODUCT FOR CANCER IMMUNOTHERAPY.LICENSE AND DEVELOPMENT AGREEMENT WITH BLISS BIOPHARMACEUTICAL (HANGZHOU) CO. LTD.  Full Article

Genscript Biotech Corp HY Profit Attributable Rises 3.3 Pct
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Genscript Biotech Corp <1548.HK>::HY PROFIT ATTRIBUTABLE $15.5 MILLION, UP 3.3%.HY REVENUE ABOUT $112.2 MILLION, UP 77 PERCENT.  Full Article

Genscript Biotech Corp Says Janssen Receives Clearance Of An Investigational New Drug Application From U.S. FDA
Wednesday, 30 May 2018 

May 30 (Reuters) - Genscript Biotech Corp <1548.HK>::JANSSEN BIOTECH, INC RECEIVED CLEARANCE OF AN INVESTIGATIONAL NEW DRUG APPLICATION FROM U.S. FDA.  Full Article

Genscript Biotech Announces Acquisition Of Customarray
Tuesday, 26 Dec 2017 

Dec 27 (Reuters) - Genscript Biotech Corp <1548.HK>::ANNOUNCES ACQUISITION OF 100% OF ENTIRE ISSUED SHARES OF CUSTOMARRAY, INC..  Full Article

Genscript Biotech Says US, Ireland Units ‍& Janssen Biotech Enter Collaboration & License Agreement ​
Thursday, 21 Dec 2017 

Dec 22 (Reuters) - Genscript Biotech Corp <1548.HK>::US, IRELAND UNITS ‍& JANSSEN BIOTECH ENTER COLLABORATION & LICENSE AGREEMENT TO DEVELOP MULTIPLE MYELOMA PRODUCTS ​.‍ACCORDING TO DEAL , JANSSEN SHALL UPFRONT PAYMENTS OF US$350 MILLION TO UNIT FOR RIGHTS GRANTED​.  Full Article

Janssen Enters Collaboration And License Agreement With China's Legend Biotech To Develop CAR-T Cancer Therapy
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Johnson & Johnson ::JANSSEN ENTERS WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH CHINESE COMPANY LEGEND BIOTECH TO DEVELOP INVESTIGATIONAL CAR-T ANTI-CANCER THERAPY.JANSSEN BIOTECH - J&J REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE GUIDANCE OF $7.25 - $7.30.FY2017 EARNINGS PER SHARE VIEW $7.28 -- THOMSON REUTERS I/B/E/S.JANSSEN - ENTERED INTO WORLDWIDE COLLABORATION, LICENSE DEAL WITH UNITS OF GENSCRIPT BIOTECH CORPORATION.JANSSEN SAYS UNDER AGREEMENT, IT WILL MAKE AN UPFRONT PAYMENT OF $350 MILLION THAT WILL BE RECORDED IN Q4.JANSSEN SAYS COS ENTERED INTO A 50/50% COST-SHARING/PROFIT-SPLIT ARRANGEMENT, EXCEPT IN GREATER CHINA.JANSSEN SAYS IN GREATER CHINA, JANSSEN AND LEGEND HAVE A 30/70 PERCENT COST-SHARING/PROFIT-SPLIT ARRANGEMENT.  Full Article

Genscript Biotech Unit's‍ Application For Investigational New Drug Accepted By China FDA
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Genscript Biotech Corp <1548.HK>::‍APPLICATION FOR INVESTIGATIONAL NEW DRUG BY UNIT ACCEPTED BY CHINA FDA.  Full Article

Genscript Biotech Corp updates on shareholding changes in GS Corp ​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Genscript Biotech Corp <1548.HK>::‍INFORMED THAT ADDITIONAL 50 MILLION SHARES & 25 MILLION SHARES OF GS CORP WERE TRANSFERRED TO ZHANG TRUST & WANG TRUST, RESPECTIVELY​.  Full Article

Genscript Biotech Corp says ‍Kanglitai informed by CFDA of approval on clinical trial
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Genscript Biotech Corp <1548.HK>:Kanglitai informed by CFDA of approval on clinical trial; approved to commence clinical studies of KLT-1101​.  Full Article

Genscript Biotech Corp updates on transfer of shares of GS Corp
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Genscript Biotech Corp <1548.HK>:Informed by GS Corp that 5 million shares & 2.5 million shares of GS Corp were transffered to Zhang Trust and Wang Trust respectively.  Full Article

Photo

Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Amgen Inc , updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.